Bezuclastinib + Sunitinib
Peak
Cogent Biosciences · Phase 3 · Recruiting · Enrollment 482
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Bezuclastinib 600 mg + sunitinib 37.5 mg | GIST after imatinib (n = 204) | 600 mg + 37.5 mg | ITT | sunitinib 37.5 mg | median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025progression-free survival hazard ratio vs sunitinib: 0.5 HR, data cutoff 09.30.2025objective response rate (BICR): 46%, data cutoff 09.30.2025PFS2 hazard ratio vs sunitinib: 0.57 HR, ASCO 2026 update |
| Sunitinib 37.5 mg continuous | GIST after imatinib (n = 209) | 37.5 mg | ITT | n/r | median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025objective response rate (BICR): 26%, data cutoff 09.30.2025 |